GEN Exclusives

More »

GEN News Highlights

Back to Item »

Novartis Shells Out $210M for Two of Incyte’s Hematology-Oncology Candidates

Deal covers non-U.S. development of Phase III-stage JAK1/JAK2 inhibitor, and global rights to cMET antagonist.

Forward this item to a colleague:


(Separate multiple addresses by commas)


(Separate multiple addresses by commas)


GEN Jobs powered by connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
More »

Be sure to take the GEN Poll

Disclosing Clinical Trial Data

Do you believe that conducting performance audits for new drugs will incentivize pharma firms to become more transparent?

More »